Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SEMA-CardioDiab HUNGARY: A Multicentre, Prospective, Non-interventional Study to Evaluate Glycemic Control and Weight Changes in Patients With Type 2 Diabetes Initiating Treatment With Oral Semaglutide by Cardiologists or Diabetologists as Part of Local Clinical Practice in Hungary

NCT06269120 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT06269120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06269120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SEMA-CardioDiab HUNGARY: A Multicentre, Prospective, Non-interventional Study to Evaluate Glycemic Control and Weight Changes in Patients With Type 2 Diabetes Initiating Treatment With Oral Semaglutide by Cardiologists or Diabetologists as Part of Local Clinical Practice in Hungary
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
September 30, 2024
Completion date
May 5, 2026
Enrollment
243 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes